Daniel E. Stone Discloses 12.96% Stake in Scinai Immunotherapeutics

TL;DR

**Daniel E. Stone owns 12.96% of Scinai Immunotherapeutics, a big individual bet.**

AI Summary

Daniel E. Stone, an individual investor, has filed an Amendment No. 2 to Schedule 13G, reporting a beneficial ownership of 624,000 Ordinary ADS Shares in Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) as of December 31, 2023. This represents a significant 12.96% stake in the company, based on 4,814,425 shares outstanding as of January 15, 2024. This substantial ownership by a single individual could signal strong conviction in Scinai's future, potentially influencing investor sentiment and stock performance.

Why It Matters

A large individual ownership stake like this can indicate a strong belief in the company's prospects, potentially attracting other investors and influencing the stock's perceived value.

Risk Assessment

Risk Level: low — This filing indicates a significant ownership stake by an individual, which is generally not a direct risk but rather an indicator of investor confidence.

Analyst Insight

Investors should note Daniel E. Stone's substantial 12.96% stake in Scinai Immunotherapeutics Ltd. as of December 31, 2023. This could be a positive signal, suggesting a knowledgeable investor sees value. Further research into Daniel E. Stone's investment history and Scinai's recent developments would be prudent.

Key Numbers

• 624,000 — Shares owned by Daniel E. Stone (Represents his sole voting and dispositive power in Scinai Immunotherapeutics Ltd.)
• 12.96% — Percentage of class owned (Indicates a significant individual stake in Scinai Immunotherapeutics Ltd.)
• 4,814,425 — Total outstanding shares (The denominator used to calculate Daniel E. Stone's percentage ownership as of January 15, 2024.)

Key Players & Entities

• Daniel E. Stone (person) — Reporting person and beneficial owner of shares
• Scinai Immunotherapeutics Ltd. (company) — The issuer of the securities
• BiondVax Pharmaceuticals Ltd. (company) — Former name of Scinai Immunotherapeutics Ltd.
• 624,000 (dollar_amount) — Number of shares beneficially owned by Daniel E. Stone
• 12.96% (dollar_amount) — Percentage of class represented by Daniel E. Stone's ownership
• 4,814,425 (dollar_amount) — Total issued and outstanding shares of the Issuer as of January 15, 2024
• December 31, 2023 (date) — Date of event which requires filing of this statement
• January 15, 2024 (date) — Date used to calculate outstanding shares for percentage ownership

Forward-Looking Statements

• The significant individual ownership by Daniel E. Stone could lead to increased investor confidence in Scinai Immunotherapeutics Ltd. (Scinai Immunotherapeutics Ltd.) — medium confidence, target: Within the next 6-12 months

FAQ

Filing Documents

• sc13a2.htm (SC 13G/A) — 33KB
• 0000912282-24-000070.txt ( ) — 35KB

(a). Name of Issuer

Item 1 (a). Name of Issuer: Scinai Immunotherapeutics Ltd., formerly BiondVax Pharmaceuticals Ltd. (the "Issuer")

(b). Address of Issuer's Principal Executive Offices

Item 1 (b). Address of Issuer's Principal Executive Offices: Jerusalem Biopark, 2 nd Floor Hadassah Ein Kerem Campus Jerusalem L3 00000

(a). Name of Person Filing

Item 2 (a). Name of Person Filing: Daniel E. Stone

(b). Address of Principal Business Office or, if None, Residence

Item 2 (b). Address of Principal Business Office or, if None, Residence: 1200 Brickell Avenue, #1470 Miami, FL 33131

(c). Citizenship

Item 2 (c). Citizenship: United States

(d). Title of Class of Securities

Item 2 (d). Title of Class of Securities: Ordinary ADS Shares

(e). CUSIP Number

Item 2 (e). CUSIP Number: 09073Q204 Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under Section 15 of the Act; (b) Bank as defined in Section 3(a)(6) of the Act; (c) Insurance Company as defined in Section 3(a)(19) of the Act; (d) Investment Company registered under Section 8 of the Investment Company Act; (e) Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) Employee benefit plan or endowment plan in accordance with Rule 13d-1(b)(1)(ii)(F); (g) Parent holding company or control person, in accordance with Rule 13d-1(b)(1)(ii)(G); (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940: (j) Group, in accordance with Rule 13d-1(b)(1)(ii)(j). X If this statement is filed pursuant to Rule 13d-1(c), check this box. Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities identified in Item 1. (a) Amount beneficially owned: 624,000 (b) Percent of class: 12.96% (b) Number of shares as to which such person has: (i) Sold power to vote or to direct the vote: 624,000 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 624,000 (iv) Shared power to dispose or to direct the disposition of: 0 Instruction. For computations regarding securities which represent a right to acquire an underlying security, see Rule 13d-3(d)(1). Item 5. If the statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ]. Item 6.

Certification

Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. January 24, 2024 (Date) /s/ Daniel E. Stone Daniel E. Stone

View Full Filing

View this SC 13G/A filing on SEC EDGAR